William Erwin
Overview
Explore the profile of William Erwin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ravizzini G, Erwin W, De Palatis L, Martiniova L, Subbiah V, Paolillo V, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760501
P-cadherin is associated with a wide range of tumor types, making it an attractive therapeutic target. FF-21101 is a human-mouse chimeric monoclonal antibody (mAb) directed against human P-cadherin, which has...
2.
Subbiah V, Erwin W, Mawlawi O, McCoy A, Wages D, Wheeler C, et al.
Clin Cancer Res
. 2020 Aug;
26(22):5830-5842.
PMID: 32816889
Purpose: Y-FF-21101 is an Yttrium-90-conjugated, chimeric mAb that is highly specific for binding to human placental (P)-cadherin, a cell-to-cell adhesion molecule overexpressed and associated with cancer invasion and metastatic dissemination...
3.
Jimenez C, Erwin W, Chasen B
Cancers (Basel)
. 2019 Jul;
11(7).
PMID: 31330766
Low-specific-activity iodine-131-radiolabeled metaiodobenzylguanidine (I-131-MIBG) was introduced last century as a potential systemic therapy for patients with malignant pheochromocytomas and paragangliomas. Collective information derived from mainly retrospective studies has suggested that...
4.
Stewart K, Chasen B, Erwin W, Fleming N, Westin S, Dioun S, et al.
Cancer
. 2019 Jun;
125(19):3347-3353.
PMID: 31225906
Background: The identification of extrauterine disease is critical to the management of patients with high-risk endometrial cancer. The purpose of the current study was to determine the accuracy of preoperative...
5.
Metyko J, Erwin W, Landsberger S
Appl Radiat Isot
. 2016 Mar;
112:62-8.
PMID: 27015651
A general-purpose nuclear medicine dose calibrator was assessed as a potential replacement for a dedicated air-communicating well-type ionization chamber (brachytherapy source strength verification instrument) for (125)I seed source strength verification...
6.
Metyko J, Erwin W, Poston Jr J, Jimenez S
Health Phys
. 2014 Oct;
107(5 Suppl 3):S177-80.
PMID: 25272027
Three different 90Y internally administered radionuclide therapies are currently used in both standard-of-care and clinical trial procedures atMD Anderson Cancer Center. TheraSphere and SIR-Spheres therapies utilize 90Y-labeled microspheres, while Zevalin...
7.
Nanoporous TiO2 nanoparticle assemblies with mesoscale morphologies: nano-cabbage versus sea-anemone
Darbandi M, Gebre T, Mitchell L, Erwin W, Bardhan R, LeVan M, et al.
Nanoscale
. 2014 Apr;
6(11):5652-6.
PMID: 24760418
We report the novel synthesis of nanoporous TiO2 nanoparticle ensembles with unique mesoscale morphologies. Constituent nanoparticles evolved into multifaceted assemblies, exhibiting excellent crystallinity and enhanced photocatalytic activity compared with commercial...
8.
Busse N, Erwin W, Pan T
Med Phys
. 2013 Dec;
40(12):122503.
PMID: 24320539
Purpose: The authors sought to evaluate a simple, semiautomated lung mass estimation method using computed tomography (CT) scans obtained using a variety of acquisition techniques and reconstruction parameters for mass...
9.
Metyko J, Williford J, Erwin W, Poston Jr J, Jimenez S
Health Phys
. 2012 Oct;
103(5 Suppl 3):S204-8.
PMID: 23026974
Yittrium-90 microsphere brachytherapy procedures have increased in number due to their efficacy in treating some unresectable metastatic liver tumors. The discovery of long-lived impurities in two microsphere products, first reported...
10.
Winter J, Inwards D, Spies S, Wiseman G, Patton D, Erwin W, et al.
J Clin Oncol
. 2009 Mar;
27(10):1653-9.
PMID: 19255322
Purpose: To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 ((90)Y) ibritumomab tiuxetan in combination with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy with autologous...